Univariate and Multivariate Analyses of Overall Survival
| Survival analysis | Patients (n) | HR | 95% CI | P |
| Univariate | ||||
| Diagnosis based on 18F-FET PET | 127 | 4.997 | 2.139–11.675 | <0.001 |
| IDH status | ||||
| IDH-wild-type | 70 | 1.000 | ||
| IDH-mutant | 51 | 0.181 | 0.091–0.363 | <0.001 |
| MGMT promoter methylation status | ||||
| Unmethylated | 40 | 1.000 | ||
| Methylated | 57 | 0.493 | 0.278–0.877 | 0.016 |
| WHO grade | 125 | 3.859 | 2.230–6.678 | <0.001 |
| Age (y) | 127 | 1.043 | 1.020–1.066 | <0.001 |
| KPS (%) | 127 | 0.965 | 0.940–0.990 | 0.007 |
| Number of glioma recurrences before 18F-FET PET scan | 127 | 1.051 | 0.792–1.395 | NS |
| Interval between last therapy and 18F-FET PET scan (d) | 124 | 0.997 | 0.996–0.999 | 0.001 |
| Multivariate | ||||
| Diagnosis based on 18F-FET PET | 3.424 | 1.446–8.109 | 0.005 | |
| WHO grade | 2.143 | 1.212–3.792 | 0.009 | |
| IDH status | 0.412 | 0.210–0.808 | 0.010 | |
| KPS (%) | 0.975 | 0.950–1.001 | 0.057 |
HR = hazard ratio; CI = confidence interval; KPS = Karnofsky performance status; NS = not statistically significant.